Just Say No

A special committee of Genentech's board asks the company's investors to reject Roche's hostile bid, reports the Wall Street Journal. Genentech says that the hostile Roche offer, at $86.50 a share, is "inadequate and not in the best interest of shareholders" and undervalues Genentech's financial outlook, its history of developing new medicines, and its product pipeline. Roche responded to the committee's recommendation by saying Roche has made its case and it is now up to the investors.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.